Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation 
UK Consumer Confidence Weakens Amid Middle East Conflict and Rising Living Costs 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion 
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
Asian Currencies Stay Muted as Dollar Holds Firm Amid Iran Uncertainty 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Federal Reserve Balance Sheet Reduction: Brookings Research Outlines Possible Path Forward 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Asian Currencies Weaken as Dollar Rebounds Amid Middle East Uncertainty and Japan Inflation Data 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
